FDA Issues CRL for Oxylanthanum Carbonate - Summary - MDSpire
Advertisement
FDA Issues CRL for Oxylanthanum Carbonate
The action relates to previously identified third-party manufacturing deficiencies rather than concerns about the clinical efficacy or safety data, according to the company.
To report on the FDA's Complete Response Letter regarding Unicycive Therapeutics' New Drug Application for oxylanthanum carbonate.
Approach:
FDA Response: The FDA issued a Complete Response Letter (CRL) for the resubmitted New Drug Application (NDA) for oxylanthanum carbonate.
Deficiencies Identified: The CRL relates to deficiencies at a third-party manufacturing vendor, previously noted in a prior CRL from June 2025.
Clinical Data: The FDA did not identify concerns regarding clinical efficacy or safety data and did not request additional data.
Manufacturing Inspection: The FDA did not inspect the third-party manufacturing facility during the review of the resubmitted NDA.
Company's Belief: Unicycive believed that the third-party vendor had made progress in resolving deficiencies and demonstrated inspection readiness.
Ongoing Discussions: Labeling discussions with the FDA are ongoing, with the most recent communication received on June 29 regarding carton and container labeling.
NDA Support: The NDA is supported by data from various studies, including a phase 1 study and a tolerability study in patients with chronic kidney disease.
Key Findings:
The CRL is based on manufacturing deficiencies, not clinical efficacy or safety concerns.
The FDA did not inspect the third-party manufacturing facility during the review.
Labeling discussions with the FDA are still ongoing.
Interpretation:
The FDA's concerns are focused on manufacturing processes rather than the drug's clinical data.
Limitations:
The CRL does not address the clinical efficacy or safety of oxylanthanum carbonate.
The third-party manufacturing vendor's readiness remains unverified by an FDA inspection.
Conclusion:
Unicycive Therapeutics continues to seek FDA approval for oxylanthanum carbonate through the 505(b)(2) regulatory pathway.
A review of 56 qualitative studies found residents' emotional experiences were influenced by interactions among training demands, workplace relationships, and their evolving professional identity.
These 10 states reported physician residency completion totals, physician retention rates, or residency Match fill rates identified in graduate medical education data.
